145 results on '"Greenberg, Michael L."'
Search Results
2. The CXC Chemokine Stromal Cell-Derived Factor 1 is not Responsible for CD8 + T Cell Suppression of Syncytia-Inducing Strains of HIV-1
3. Resistance to Enfuvirtide and Other HIV Entry Inhibitors
4. Enfuvirtide: from basic science to FDA approval
5. Noncytolytic CD8 T cell-mediated suppression of HIV replication
6. Tropism-Independent Protection of Macaques against Vaginal Transmission of Three SHIVs by the HIV-1 Fusion Inhibitor T-1249
7. Design of Helical, Oligomeric HIV-1 Fusion Inhibitor Peptides with Potent Activity against Enfuvirtide-Resistant Virus
8. HIV-1 Coreceptor Use in Triple-Class Treatment-Experienced Patients: Baseline Prevalence, Correlates, and Relationship to Enfuvirtide Response
9. T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen
10. Dicyclohexylamine-Induced Shift of Biosynthesis from Spermidine to Spermine in Plant Protoplasts
11. Vaccine Protection of Chimpanzees Against Challenge with HIV-1-Infected Peripheral Blood Mononuclear Cells
12. Spermidine, an Intrinsic Component of Turnip Yellow Mosaic Virus
13. Mechanisms for HIV-1 entry: Current strategies to interfere with this step
14. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy
15. Antibody responses and virus escape: implications for HIV-1 vaccine and therapeutic design
16. The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1
17. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates
18. Resistance to enfuvirtide, the first HIV fusion inhibitor
19. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen
20. Erythropoietic and Reticuloendothelial Function in Bone Marrow in Dogs
21. Case report 621
22. Oligoclonal CD8 Lymphocytes from Persons with Asymptomatic Human Immunodeficiency Virus (HIV) Type 1 Infection Inhibit HIV-1 Replication
23. Probes for Examining the Structure and Function of Human S-Adenosylhomocysteine Hydrolase, and for Isolation of cDNA
24. Effects of Purine Nucleosides on Differentiation in Lymphohematopoietic Stem Cell Leukemia
25. Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure
26. [CD8.sup.+] T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression
27. The Ability of Certain SIV Vaccines to Provoke Reactions Against Normal Cells
28. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase
29. Use of Polyethylene Glycol-Modified Uricase (PEG-Uricase) to Treat Hyperuricemia in a Patient with Non-Hodgkin Lymphoma
30. In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth
31. Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia
32. Safety and Efficacy of Enfuvirtide in Combination with Darunavir-Ritonavir and an Optimized Background Regimen in Treatment-Experienced Human Immunodeficiency Virus-Infected Patients: the Below the Level of Quantification Study
33. Impact of the Enfuvirtide Resistance Mutation N43D and the Associated Baseline Polymorphism E137K on Peptide Sensitivity and Six-Helix Bundle Structure
34. Initiation of Human Immunodeficiency Virus Type 1 (HIV-1) Transcription is Inhibited by Noncytolytic CD8+ Suppression
35. Enfuvirtide: from basic science to FDA approval.
36. Immunologic and Virologic Analyses of an Acutely HIV Type 1-Infected Patient with Extremely Rapid Disease Progression
37. Molecular Basis for Cell Tropism of CXCR4-Dependent Human Immunodeficiency Virus Type 1 Isolates
38. Evolution of the Human Immunodeficiency Virus Type 1 Envelope during Infection Reveals Molecular Corollaries of Specificity for Coreceptor Utilization and AIDS Pathogenesis
39. Monoclonal Antibodies That Bind to the Core of Fusion-Active Glycoprotein 41
40. Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1
41. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization 1 1Edited by I. Wilson
42. Herpesvirus Saimiri Transformation of HIV Type 1 Suppressive CD8+Lymphocytes from an HIV Type 1-Infected Asymptomatic Individual
43. Noncytolytic CD8 T cell-mediated suppression of HIV replication
44. Structural Rearrangements in the Transmembrane Glycoprotein after Receptor Binding
45. CD8+T Lymphocyte-Mediated Inhibition of HIV-1 Long Terminal Repeat Transcription: A Novel Antiviral Mechanism
46. Detection of Anti-Human Cell Antibodies in Sera from Macaques Immunized with Whole Inactivated Virus
47. Cloning of the gene encoding Leishmania donovaniS-adenosylhomocysteine hydrolase, a potential target for antiparasitic chemotherapy
48. PHARMACOLOGIC PURGING OF MALIGNANT T CELLS FROM HUMAN BONE MARROW USING 9-β-D-ARABINOFURANOSYLGUANINE
49. Metabolism, Toxicity, and Anti‐HIV Activity of 2′‐Deoxy‐3′‐Thia‐Cytidine (BCH‐189) in T and B Cell Lines
50. Trisomy 13 in bone marrow cells in acute myelocytic leukemia and myelofibrosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.